Crizotinib in ROS1 rearranged or MET deregulated Non-Small-Cell Lung Cancer (NSCLC): Preliminary results of the METROS trial

Landi, L.; Chiari, Rita; Delmonte, Angelo; Morabito, A.; Tamberi, Stefano; Barbieri, Fausto; Buosi, R.; Gridelli, Cesare; Tiseo, M.; Gebbia, Vittorio; Fontanini, G.; Crinò, Lucio; Cappuzzo, F.

doi:10.1093/annonc/mdw332.07

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A case report of one 90-year old male with ROS-1 rearranged stage IIIA NSCLC treated with crizotinib, achieved a partial response, despite requiring a 50% dose reduction [ 42 ]. Several trials of crizotinib in this setting are ongoing, many of which include patients at extremes of age or PS2, with preliminary results consistent with previously reported efficacy, and subgroup analyses awaited [ 43 , 44 , 45 , 46 ]. A phase II study of ceritinib in 32 patients with previously-treated ROS-1 mutated NSCLC included patients up to 79 years and 4/32 patients with PS 2 [ 47 ].…”

Section: Targeted Therapy In Elderly And/or Ps2 Patients With Advamentioning

confidence: 75%

A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC

Carmichael

Mak

O’Brien

2018

Cancers

View full text Add to dashboard Cite

Until recently, chemotherapy has remained the mainstay of treatment for the majority of patients with advanced non-small cell lung cancer (NSCLC). Excellent responses have been observed with immune-checkpoint inhibitors, and targeted treatments for those tumours with actionable mutations, resulting in a paradigm shift in the treatment approach for these patients. Elderly patients and those with poor performance status (PS), such as Eastern Cooperative Oncology Group (ECOG) 2, have historically been excluded from clinical trials due to poor outcomes. There is therefore a lack of data to define the optimal treatment strategy for these patients. Due to improved tolerability of novel therapies, inclusion of these patients in clinical trials has increased, and sub-group analyses have identified many treatments demonstrating potential activity. Here, we summarise key recent advances in the treatment of NSCLC, specifically evaluating their efficacy and tolerability in these patient cohorts.

show abstract

Section: Targeted Therapy In Elderly And/or Ps2 Patients With Advamentioning

confidence: 75%

A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC

Carmichael

Mak

O’Brien

2018

Cancers

View full text Add to dashboard Cite

show abstract

An elderly female patient with ROS1 rearrangement primary lung adenocarcinoma and breast carcinoma: a rare case report and review of the literature

Xiao

Qin

Zhang

et al. 2019

Precision Clinical Medicine

View full text Add to dashboard Cite

We report the case of a 90-year-old female patient who was suffering from c-ros oncogene 1 (ros-1) rearrangement adenocarcinoma and breast cancer. After about 14 months of a reduced dose of crizotinib treatment, she had a stable disease according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). This patient’s case demonstrates that ros-1 rearrangements are not limited to patients of young age. In addition, this case indicates that crizotinib, as second-line, or even first-line, treatment may be effective and manageable in elderly patients. Furthermore, for elderly patients carrying a ros1 fusion, a reduced dose of crizotinib may be efficacious rather than a resistance factor. Based on our findings, we recommend that elderly patients with advanced lung adenocarcinoma should be considered for inclusion in molecular screening for ros-1 translocation, especially for never-smokers negative for epidermal growth factor receptor (egfr) mutation and the fusion between echinoderm microtubule associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK). This deserves attention because the population is aging, with increasing incidence and morbidity of multiple primary malignant tumors. Neglect of breast nodules at the onset is one of the limitations of our case, as combination of primary lung cancer with breast cancer is common. Above all, use of antiestrogens before and after the diagnosis of non-small-cell lung cancer is related to a reduced risk of lung cancer mortality. Therefore, careful attention should always be paid to these cases.

show abstract

Crizotinib in ROS1 rearranged or MET deregulated Non-Small-Cell Lung Cancer (NSCLC): Preliminary results of the METROS trial

Cited by 2 publications

References 0 publications

A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC

A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC

An elderly female patient with ROS1 rearrangement primary lung adenocarcinoma and breast carcinoma: a rare case report and review of the literature

Contact Info

Product

Resources

About